A61K 40/4257
Mucins
Official title: {Mucins, e.g. MUC-1}
A61K40/4257 (Mucins) appears on 146 US grants and 292 published applications in this corpus.
Search patents in A61K- Granted patents
- 146
- Published applications
- 292
- Assignees
- 113
- Inventors
- 437
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 4 |
| 2003 | 2 | 1 |
| 2004 | 1 | 4 |
| 2005 | 0 | 2 |
| 2006 | 1 | 3 |
| 2007 | 0 | 3 |
| 2008 | 0 | 5 |
| 2009 | 2 | 5 |
| 2010 | 2 | 3 |
| 2011 | 2 | 4 |
| 2012 | 3 | 3 |
| 2013 | 2 | 4 |
| 2014 | 1 | 5 |
| 2015 | 5 | 3 |
| 2016 | 5 | 5 |
| 2017 | 4 | 11 |
| 2018 | 7 | 12 |
| 2019 | 5 | 21 |
| 2020 | 12 | 30 |
| 2021 | 15 | 35 |
| 2022 | 12 | 24 |
| 2023 | 14 | 29 |
| 2024 | 13 | 35 |
| 2025 | 18 | 24 |
| 2026 | 20 | 17 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy22 Sep 2026US 12,742,152 B2Angeles Therapeutics, Inc.
- Anti-MUC1-C antibodies and CAR-T structures15 Sep 2026US 12,735,503 B2TeneoBio, Inc.
- Presenting cell and use thereof in cell therapy11 Aug 2026US 12,702,708 B2Innovative Cellular Therapeutics Holdings, Ltd.
- Anti-MUC1 compositions and methods of use21 Jul 2026US 12,686,726 B2Poseida Therapeutics, Inc.
- Polypeptide specific for mucin 1 and use thereof23 Jun 2026US 12,661,402 B2LG Chem.Ltd.
- Methods and materials for treating cancer24 Sep 2026US 2026/0284192 A1Mayo Foundation for Medical Education and Research
- Plasmacytoid dendritic cells for treating cancer17 Sep 2026US 2026/0272977 A1Pdc Line Pharma
- Plasmacytoid dendritic cells and immune checkpoint inhibitor for cancer treatment13 Aug 2026US 2026/0232798 A1Pdc Line Pharma
- Chimeric receptors and methods of use thereof13 Aug 2026US 2026/0232803 A1Senti Biosciences, Inc.
- Parallel chimeric antigen receptors (pcars) and adaptor chimeric antigen receptors comprising alternative signalling domains and methods of use thereof16 Jul 2026US 2026/0201060 A1King's College London
Most cited
By later US patents
- Compositions, methods, and computer systems related to making and administering modified T cells107US 9,499,855 B2Elwha LLC · 2016
- Therapeutic and diagnostic cloned MHC-unrestricted receptor specific for the MUC1 tumor associated antigen46US 7,655,461 B2University of Pittsbugh — Of the Commonwealth System of Higher Education · 2010
- Human cytotoxic T-lymphoctye epitope and its agonist eptiope from the non-variable number of tandem repeat sequence of MUC-139US 7,999,071 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2011
- Lipid-modified muc-1 derivatives28US 6,600,012 B1Biomira, Inc. · 2003
- Protein modification of living cells using sortase27US 10,260,038 B2Whitehead Institute for Biomedical Research · 2019